About My Health Careers Internship MedBlogs Contact us

Gastrointestinal Hormones may Help Ease Symptoms of Liver Diseases

by Rishika Gupta on March 9, 2018 at 2:20 PM
Font : A-A+

Gastrointestinal Hormones may Help Ease Symptoms of Liver Diseases

Gastrointestinal hormone treatment significantly reduced the liver fat in patients with the fatty liver disease, finds a new study. The findings of this study are published in Journal of Lancet.


Through a randomized, double-blind, placebo-controlled phase II clinical trial, researchers at University of California San Diego School of Medicine report that small doses of NGM282, a non-tumorigenic variant of an endocrine gastrointestinal hormone, can significantly and rapidly decrease liver fat content in patients with Non-alcoholic fatty liver disease (NAFLD)and Non-alcoholic steatohepatitis (NASH)

The findings, they say, represent an important proof-of-concept for the compound as there are currently no Food and Drug Administration-approved treatments for NAFLD and NASH.

"Patients with NAFLD and NASH have had limited treatment options for years. What the results of our phase II study show is a promising future where NGM282 may be able to provide relief to these patients," said senior author Rohit Loomba, MD, director of the UC San Diego NAFLD Research Center and director of hepatology at UC San Diego School of Medicine.

NAFLD includes a spectrum of chronic hepatic (liver) diseases, with NASH being the most aggressive type. The cause of both NAFLD and NASH remains a mystery, but certain health conditions, including obesity and type 2 diabetes, can be predisposing factors. It is estimated that tens of millions of people globally are living with NAFLD and NASH. Weight loss and a healthier diet are the current standards of care.

The study involved 166 patients, ages 18 to 75, at 18 different hospitals, gastroenterology or liver clinics in the United States and Australia. Participants had confirmed NAFLD or NASH biopsies and a liver fat content of at least 8 percent. Participants were randomly assigned by a web-based computer system on a 1:1:1 model to receive 3 milligrams (mg) or 6 mg of NGM282 or a placebo injection once per day. They were then monitored biweekly over a three-month period.

Loomba explained that both the 3 mg and 6 mg doses of NGM282 produced a rapid and sustained change of liver fat content. "The most promising outcome of this study was the absolute change in liver fat that we were able to measure using advanced magnetic resonance imaging (MRI) methods previously developed and validated in pilot studies conducted at the UC San Diego NAFLD Research Center. Looking from baseline to week 12, we consider participants who had a liver fat reduction of at least either a 5 percent absolute reduction or greater than 30 percent relative reduction from baseline to be clinically significant."

To measure the reduction in liver fat, researchers used hepatic MRIs with proton density fat fraction. This type of imaging is extremely sensitive to changes in liver composition compared with traditional assessments of tissue samples under a microscope.

NMG282 is a non-tumorigenic variant of fibroblast growth factor 19, an endocrine, gastrointestinal hormone that regulates stomach acid and is responsible for glucose and lipid metabolism in the body. It is suspected that NMG282 is able to improve liver steatosis as well as inflammation and fibrosis commonly associated with NAFLD and NASH.

Study participants generally tolerated NMG282 with reported side effects including pain at the injection site, diarrhea, abdominal pain, and nausea. No life-threating events or patient deaths occurred during the study. The authors said additional, and longer trials are needed to fully understand the efficacy and effectiveness of NGM282.

"Moving forward, we are continuing the development of this compound for the treatment of NASH-related fibrosis," said Loomba. "In this, we hope to further examine the efficacy of this hormone in improving liver histology based end-points in patients with biopsy-proven NASH with fibrosis."

Source: Eurekalert

News A-Z
News Category
What's New on Medindia
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
World AIDS Day 2021 - End Inequalities, End AIDS
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Hepatitis A Liver Wilson's Disease Milk Thistle Current Treatments for Liver Cancer Fatty Liver Disease: A Growing Health Problem in India Living Donor Liver Transplant: What Are the Risks? Liver Failure 

Recommended Reading
Mini-liver Organoid Offers Better Insights into Liver Diseases
The creation of the most sophisticated human liver model gives scientists a better chance to liver ....
Treatment Strategies For Effective Management of Liver Diseases
Currently, there is no general agreement on how acute hepatitis should be treated....
'World Liver Day' Creates Awareness to Prevent Liver Diseases
April 19th is celebrated as World Liver day every year. According to WHO, liver disease is the 10th ...
Gene Therapy for Metabolic Liver Diseases Shows Promising Results in Pigs
Through gene therapy, the corrected liver cells were transplanted into the diseased liver of pigs .....
Current Treatments for Liver Cancer
Current Treatments for Liver Cancer (also known as hepatoma or hepatocellular carcinoma) can result ...
Fatty Liver Disease: A Growing Health Problem in India
Non alcoholic fatty liver disease (NAFLD) is the leading cause of liver dysfunction worldwide and is...
Hepatitis A
Hepatitis A is the most benign of the hepatitis viruses and usually has no long term side effects. H...
Liver Failure
Liver failure occurs when the liver loses its ability to perform its normal functions of regeneratio...
Living Donor Liver Transplant: What Are the Risks?
The risk of dying as a result of a living donor liver segment removal is between 0.2-2.0%. The risk ...
Milk Thistle
Milk Thistle is a resourceful natural plant which has many medicinal benefits. In herbal medication ...
Wilson's Disease
This is a rare inherited systemic disorder of copper metabolism, affecting the liver mainly before o...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use